Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2021-05-12 OssDsign OssDsign AB: OssDsign raises SEK 270 million in oversubscribed rights issue and utilised over-allotment option Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 12 May 2021 | OssDsign

OssDsign AB: OssDsign raises SEK 270 million in oversubscribed rights issue and utilised over-allotment option

The result of the Rights Issue of maximum 31,033,044 shares shows that 29,671,460 new shares, corresponding to approximately 96 percent of the Rights Issue, have been subscribed for with subscription rights. Additionally, 27,587,742 shares were subscribed for without subscription rights of which 1,361,584 shares, corresponding to approximately 4 percent of the Rights Issue, have been allotted to investors that have subscribed for shares without subscription rights. The subscription ratio in the Rights Issue amounted to approximately 185 percent. The Rights Issue is thus oversubscribed and hence, no guarantee commitments will be utilised. 

”We appreciate the strong support from our current shareholders and are delighted to welcome a number of new strategic and institutional investors, which will enable us to execute on OssDsign’s new strategy, ASCENT25”, said Morten Henneveld, CEO of OssDsign.

Allotment of shares subscribed for without subscription rights has been made in accordance with the resolved allotment principles. Notice of allotment of shares subscribed for without subscription rights will only be sent to those who have been allotted shares. Payment shall be made in accordance with the instructions on the contract note. Nominee-registered shareholders will receive notice of allotment and payment in accordance with the procedures of each nominee.

Due to the oversubscription of the Rights Issue, the Board of Directors of the Company has exercised the Over-allotment Option to meet additional demand from strategic investors through a directed issue of 3,875,000 new shares. Shares in the Over-allotment Option were allotted to strategic and institutional investors. 

Following the Rights Issue and Over-allotment Option, OssDsign’s share capital will increase by approximately SEK 2,181,753 to approximately SEK 3,567,157 and the number of shares will increase by 34,908,044 shares to 57,074,504 shares.

Trading in paid subscribed shares (BTA) on Nasdaq First North Growth continue up to and including the day the Swedish Companies Registration Office has registered the Rights Issue and BTA as re-registered as shares, which is expected to take place around week 21. In order to facilitate the delivery of shares to the investors in the Over-allotment Option, Karolinska Development AB and SEB Venture Capital have together lent 3,875,000 shares to ABG Sundal Collier. The shares will be returned after the Over-allotment Option has been registered with the Swedish Companies Registration Office, which is expected take place around week 20.

Financial and legal advisors
ABG Sundal Collier acted as Sole Global Coordinator and Bookrunner for the Rights Issue. Setterwalls acted as the legal advisor to OssDsign.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the Company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

The information was submitted for publication, through the agency of the contact persons set out above, on 12 May 2021, 08:00 CET.

About OssDsign
OssDsign’s vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborate with surgeons to engineer better healing by integrating biomaterials with clinical design. OssDsign is headquartered in Sweden but supplies hospitals globally with implants for use in cranial reconstructions and other orthopaedic surgery applications.

OssDsign (OSSD) is listed on First North since May 24, 2019. For more information, see http://www.ossdsign.com

Important Information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction where such offer would be considered illegal. This press release does not constitute an offer to sell or an offer to buy or subscribe for shares issued by the Company in any jurisdiction where such offer or invitation would be illegal. In a member state within the European Economic Area (”EEA”), securities referred to in the press release may only be offered in accordance with applicable exemptions under Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the ”Prospectus Regulation”).

This press release is not an offer or invitation to acquire or subscribe for shares or other securities in the United States. The securities that have been mentioned in this release are not allowed to be sold in the United States without registration, or without application of an exception from registration, according to the applicable U.S. Securities Act from 1933 (”Securities Act”), or as a part of a transaction that is not covered by the registration requirements according to the Securities Act. There is no intention to register any shares or securities mentioned herein in the United States or to announce a public offering of such securities in the United States. The information in this press release shall not be published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Japan, Canada, Hong Kong, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction in which the release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would demand additional registration or other actions according to Swedish law. Acts in contrary to this instruction can constitute a crime according to applicable securities laws.

The prospectus that has been prepared in connection with the Rights Issue described in this press release was published by the Company on April 20, 2021. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on OssDsign’s website, https://www.ossdsign.com/ . The approval of the prospectus by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the shares. This release is however not a prospectus in accordance to the definition in the Prospectus Regulation. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the prospectus. Thus, investors are encouraged to review the prospectus in its entirety. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement. OssDsign has not authorized any offer to the public of shares or rights in any other member state of the EEA than Sweden. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares. An investment decision to acquire or subscribe for shares in the Rights Issue shall only be made based on publicly available information.

To the extent this press release contains forward-looking statements, such statements does not constitute facts and are characterized by words such as ”shall”, ”expect”, ”believe” ”assess”, ”intend”, ”estimate” and similar expressions. Such statements reflects OssDsign’s intentions, views or present expectations or assumptions. Such forward-looking statements are based on OssDsign’s current plans, estimates and projections, which have been made to the best of OssDsign’s ability. However, OssDsign does not assert that these statements will be correct in the future. Forward-looking statements are associated with risks and uncertainties which are difficult to predict and which generally cannot be affected by OssDsign. It should be contemplated that actual events or outcomes may differ materially from what is included or expressed in such forward-looking statements.

2021-05-12 OssDsign OssDsign AB: OssDsign tillförs 270 MSEK genom övertecknad företrädesemission och utnyttjad övertilldelningsoption Pressreleaser Ladda ner | Visa Stäng
2021-05-05 OssDsign OssDsign AB: Ny vetenskaplig publikation bekräftar benformation med OssDsign Cranial PSI-implantat Pressreleaser Ladda ner | Visa Stäng
2021-05-05 OssDsign OssDsign AB: New scientific paper further confirms osteointegration of OssDsign Cranial PSI implants Pressreleaser Ladda ner | Visa Stäng
2021-04-20 OssDsign OssDsign AB: OssDsign offentliggör prospekt i samband med fullt garanterad företrädesemission Pressreleaser Ladda ner | Visa Stäng
2021-04-20 OssDsign OssDsign AB: OssDsign publishes prospectus in connection with a fully guaranteed rights issue Pressreleaser Ladda ner | Visa Stäng
2021-04-19 OssDsign OssDsign AB (publ) publicerar delårsrapport för första kvartalet 2021 Rapporter Ladda ner | Visa Stäng
2021-04-19 OssDsign OssDsign AB (publ) publishes Q1 2021 Interim Report Rapporter Ladda ner | Visa Stäng
2021-04-09 OssDsign Kommuniké från extra bolagsstämma i OssDsign AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-04-09 OssDsign Bulletin from the extraordinary general meeting in OssDsign AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-03-12 OssDsign OssDsign AB: Anders Svensson joins OssDsign as Chief Financial Officer Pressreleaser Ladda ner | Visa Stäng
2021-03-12 OssDsign OssDsign AB: Anders Svensson ansluter till OssDsign som Chief Financial Officer Pressreleaser Ladda ner | Visa Stäng
2021-03-02 OssDsign Kallelse till extra bolagsstämma i OssDsign AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-03-02 OssDsign Notice of extraordinary general meeting in OssDsign AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-03-02 OssDsign OssDsign AB: Styrelsen för OssDsign har beslutat om en fullt garanterad företrädesemission om cirka 240 MSEK i kombination med en övertilldelningsoption om upp till cirka 30 MSEK Pressreleaser Ladda ner | Visa Stäng
2021-03-02 OssDsign OssDsign AB: OssDsign uppdaterar sin strategi och fastställer ny finansiell ambition för att driva ökad tillväxt, värdeskapande och innovation. Pressreleaser Ladda ner | Visa Stäng
2021-03-02 OssDsign OssDsign AB: The board of directors of OssDsign has resolved on a fully guaranteed rights issue of approximately SEK 240 million in combination with an over-allotment option of approximately SEK 30 million Pressreleaser Ladda ner | Visa Stäng
2021-03-02 OssDsign OssDsign AB: OssDsign updates its strategy and establishes new financial ambitions to support growth, value creation and innovation Pressreleaser Ladda ner | Visa Stäng
2021-02-11 OssDsign OssDsign AB (publ) publishes Year-end 2020 Report Pressreleaser Ladda ner | Visa Stäng
2021-02-11 OssDsign OssDsign AB (publ) publicerar Bokslutskommuniké 2020 Pressreleaser Ladda ner | Visa Stäng
2021-02-10 OssDsign OssDsign AB: OssDsign livesänder presentation av bokslutskommuniké Pressreleaser Ladda ner | Visa Stäng
2021-02-10 OssDsign OssDsign AB: OssDsign's year-end results to be presented via webcast Pressreleaser Ladda ner | Visa Stäng
2021-01-20 OssDsign OssDsign AB: New clinical data from 1,055 cranioplasty procedures with OssDsign Cranial PSI continue to show low complication rates Pressreleaser Ladda ner | Visa Stäng
2021-01-20 OssDsign OssDsign AB: Nya kliniska data från 1055 kranioplastiker med OssDsign Cranial PSI visar fortsatt låga komplikationsnivåer Pressreleaser Ladda ner | Visa Stäng
2020-11-13 OssDsign OssDsign AB: OssDsigns CFO Claes Lindblad lämnar bolaget Pressreleaser Ladda ner | Visa Stäng
2020-11-13 OssDsign OssDsign AB: OssDsign's CFO Claes Lindblad is leaving the company Pressreleaser Ladda ner | Visa Stäng
2020-11-12 OssDsign OssDsign AB: Medlemmar i OssDsigns styrelse, VD och ledningsgrupp köper aktier för 889 KSEK Pressreleaser Ladda ner | Visa Stäng
2020-11-12 OssDsign OssDsign AB: OssDsign board members, CEO and management purchase shares for 889 KSEK Pressreleaser Ladda ner | Visa Stäng
2020-11-12 OssDsign OssDsign AB: Penser Access: OssDsign - Stark avslutning på Q3'20 Pressreleaser Visa Stäng
2020-11-11 OssDsign OssDsign AB (publ) publishes Q3 2020 interim report Rapporter Ladda ner | Visa Stäng
2020-11-11 OssDsign OssDsign AB (publ) publicerar delårsrapport för tredje kvartalet 2020 Rapporter Ladda ner | Visa Stäng
2020-11-09 OssDsign OssDsign AB: OssDsign slutför förväret av det skotska benersättningsföretaget Sirakoss Pressreleaser Ladda ner | Visa Stäng
2020-11-09 OssDsign OssDsign AB: OssDsign completes acquisition of the Scottish bone graft company Sirakoss Pressreleaser Ladda ner | Visa Stäng
2020-11-04 OssDsign OssDsign AB: OssDsign håller webcast med anledning av förvärvet av Sirakoss Ltd Pressreleaser Ladda ner | Visa Stäng
2020-11-04 OssDsign OssDsign AB: OssDsign to present Sirakoss acquisition via live Webcast Pressreleaser Ladda ner | Visa Stäng
2020-11-03 OssDsign OssDsign AB: OssDsign har genomfört en riktad nyemission av aktier och tillförs härigenom cirka 65 miljoner kronor för att finansiera förvärvet av Sirakoss Pressreleaser Ladda ner | Visa Stäng
2020-11-03 OssDsign OssDsign AB: OssDsign has carried out a directed share issue raising proceeds of approximately SEK 65 million to finance the Sirakoss acquisition Pressreleaser Ladda ner | Visa Stäng
2020-11-03 OssDsign OssDsign AB: OssDsign offentliggör avsikt att genomföra en riktad nyemission som en del i finansieringen av förvärvet av Sirakoss Pressreleaser Ladda ner | Visa Stäng
2020-11-03 OssDsign OssDsign AB: OssDsign announces intention to carry out a directed share issue as part of the financing of the acquisition of Sirakoss Pressreleaser Ladda ner | Visa Stäng
2020-11-03 OssDsign OssDsign AB: OssDsign - strong sales in third quarter 2020 Pressreleaser Ladda ner | Visa Stäng
2020-11-03 OssDsign OssDsign AB: OssDsign - stark försäljning i tredje kvartalet 2020 Pressreleaser Ladda ner | Visa Stäng
2020-11-03 OssDsign OssDsign AB: OssDsign förvärvar Sirakoss och expanderar till marknad för bengraft värd 4 miljarder USD Pressreleaser Ladda ner | Visa Stäng
2020-11-03 OssDsign OssDsign AB: OssDsign acquires Sirakoss, enters USD 4 billion bone graft market Pressreleaser Ladda ner | Visa Stäng
2020-10-14 OssDsign OssDsign AB: Ny artikel i den prestigefyllda vetenskapliga tidskriften PNAS bekräftar den regenerativa potentialen i OssDsigns teknik Pressreleaser Ladda ner | Visa Stäng
2020-10-14 OssDsign OssDsign AB: New publication in high-impact scientific journal PNAS confirms the bone regenerative potential of OssDsign's technology. Pressreleaser Ladda ner | Visa Stäng
2020-09-18 OssDsign OssDsign AB: OssDsign strengthens patent coverage for OssDsign Cranial PSI in key market Pressreleaser Ladda ner | Visa Stäng
2020-09-18 OssDsign OssDsign AB: OssDsign stärker patentskyddet på huvudmarknad för OssDsign Cranial PSI Pressreleaser Ladda ner | Visa Stäng
2020-09-04 OssDsign OssDsign AB: Ny analys av OssDsign och kommande investerarpresentation Pressreleaser Ladda ner | Visa Stäng
2020-09-04 OssDsign OssDsign AB: New investment analysis of OssDsign and upcoming presentation Pressreleaser Ladda ner | Visa Stäng
2020-08-21 OssDsign OssDsign AB: OssDsign reports successful outcome at 6-month follow-up of clinical study on sinus augmentation Pressreleaser Ladda ner | Visa Stäng
2020-08-21 OssDsign OssDsign AB: OssDsign rapporterar positiva resultat vid 6 månaders uppföljning av klinisk studie på sinuslyft Pressreleaser Ladda ner | Visa Stäng
2020-08-20 OssDsign OssDsign AB: Penser Access: OssDsign -  Väntat hack i kurvan Q2'20, men tillväxten fortsätter Pressreleaser Visa Stäng
2020-08-19 OssDsign OssDsign AB (publ) publicerar delårsrapport för andra kvartalet 2020 Rapporter Ladda ner | Visa Stäng
2020-08-19 OssDsign OssDsign AB (publ) publishes Q2 2020 interim report Rapporter Ladda ner | Visa Stäng
2020-08-11 OssDsign OssDsign AB tecknar avtal med Muranaka Medical Instruments Co., Ltd., i Japan Pressreleaser Ladda ner | Visa Stäng
2020-08-11 OssDsign OssDsign AB signs business partner agreement with Muranaka Medical Instruments Co., Ltd., in Japan Pressreleaser Ladda ner | Visa Stäng
2020-06-05 OssDsign OssDsign AB: OssDsign appoints ABG Sundal Collier as Liquidity Provider Pressreleaser Ladda ner | Visa Stäng
2020-06-05 OssDsign OssDsign AB: OssDsign utser ABG Sundal Collier till likviditetsgarant Pressreleaser Ladda ner | Visa Stäng
2020-06-02 OssDsign OssDsign AB: OssDsign selected as one of the Nordic region's 50 leading companies of the future Pressreleaser Ladda ner | Visa Stäng
2020-06-02 OssDsign OssDsign AB: OssDsign utsett till ett av Nordens 50 främsta framtidsbolag 2020 Pressreleaser Ladda ner | Visa Stäng
2020-06-01 OssDsign OssDsign AB: OssDsign Announces Planned Change of Chief Executive Officer Pressreleaser Ladda ner | Visa Stäng
2020-06-01 OssDsign OssDsign AB: OssDsign genomför planerat VD-byte den 1 september 2020 Pressreleaser Ladda ner | Visa Stäng
2020-05-20 OssDsign Årsstämman har hållits i OssDsign AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-05-20 OssDsign Annual general meeting held in OssDsign AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-05-14 OssDsign OssDsign AB: Penser Access: OssDsign - Stark tillväxt i Q1'20 Pressreleaser Visa Stäng
2020-05-13 OssDsign OssDsign AB (publ) publishes Q1 2020 interim report Rapporter Ladda ner | Visa Stäng
2020-05-13 OssDsign OssDsign AB (publ) publicerar delårsrapport för första kvartalet 2020 Rapporter Ladda ner | Visa Stäng
2020-05-11 OssDsign OssDsign AB: OssDsign Cranial PSI godkänd för fullständig nationell kostnadsersättning i Japan Pressreleaser Ladda ner | Visa Stäng
2020-05-11 OssDsign OssDsign AB: OssDsign Cranial PSI granted full nationwide reimbursement in Japan Pressreleaser Ladda ner | Visa Stäng
2020-05-08 OssDsign OssDsign AB: OssDsign livesänder presentation av Q1 kvartalsrapport Pressreleaser Ladda ner | Visa Stäng
2020-05-08 OssDsign OssDsign AB: OssDsign's first quarter results to be presented live Pressreleaser Ladda ner | Visa Stäng
2020-05-06 OssDsign OssDsign AB: OssDsign utser VP of Sales för OssDsign USA, Inc för att driva fortsatt tillväxt på bolagets största marknad Pressreleaser Ladda ner | Visa Stäng
2020-05-06 OssDsign OssDsign AB: OssDsign appoints VP of Sales for OssDsign USA, Inc to drive continued growth in the company's largest market Pressreleaser Ladda ner | Visa Stäng
2020-04-20 OssDsign Notice to attend the annual general meeting in OssDsign AB (publ) to be held on May 20, 2020 Pressreleaser Ladda ner | Visa Stäng
2020-04-20 OssDsign Kallelse till årsstämma i OssDsign AB (publ) den 20 maj 2020 Pressreleaser Ladda ner | Visa Stäng
2020-04-17 OssDsign OssDsign AB: OssDsign publishes the Annual Report for 2019 Rapporter Ladda ner | Visa Stäng
2020-04-17 OssDsign OssDsign AB: OssDsign publicerar årsredovisning för 2019 Rapporter Ladda ner | Visa Stäng
2020-03-30 OssDsign OssDsign AB: OssDsign erhåller regulatoriskt godkännande i Japan och förbereder för lansering Pressreleaser Ladda ner | Visa Stäng
2020-03-30 OssDsign OssDsign AB: OssDsign receives regulatory approval and prepares for launch in Japan Pressreleaser Ladda ner | Visa Stäng
2020-03-25 OssDsign OssDsign AB: Uppdaterad finansiell kalender Pressreleaser Ladda ner | Visa Stäng
2020-03-25 OssDsign OssDsign AB: Updated financial calendar Pressreleaser Ladda ner | Visa Stäng
2020-02-14 OssDsign OssDsign AB: Penser Access: OssDsign - Fokus på tillväxt i USA Pressreleaser Visa Stäng
2020-02-13 OssDsign OssDsign AB (publ) publicerar Bokslutskommuniké 2019 Rapporter Ladda ner | Visa Stäng
2020-02-13 OssDsign OssDsign AB (publ) publishes year-end report 2019 Rapporter Ladda ner | Visa Stäng
2020-02-06 OssDsign OssDsign AB: OssDsign slutför överföringen av den kommersiella verksamheten i USA Pressreleaser Ladda ner | Visa Stäng
2020-02-06 OssDsign OssDsign AB: OssDsign completes transfer of commercial operations in the US Pressreleaser Ladda ner | Visa Stäng
2020-01-22 OssDsign OssDsign AB: OssDsign presenting at FS Markets investor meeting in Stockholm Pressreleaser Ladda ner | Visa Stäng
2020-01-22 OssDsign OssDsign AB: OssDsign presenterar på FS-Markets investerarmöte Pressreleaser Ladda ner | Visa Stäng
2019-12-02 OssDsign OssDsign AB: OssDsigns senaste investerarpresentation samt VD intervju finns nu tillgängliga Pressreleaser Ladda ner | Visa Stäng
2019-12-02 OssDsign OssDsign AB: OssDsign's latest investor presentation and CEO-interview now available Pressreleaser Ladda ner | Visa Stäng
2019-11-25 OssDsign OssDsign AB: OssDsign: Penser Access: OssDsign - Lösningen på ett mångtusenårigt problem Pressreleaser Visa Stäng
2019-11-19 OssDsign OssDsign AB (publ) publishes Q3 2019 interim report Rapporter Ladda ner | Visa Stäng
2019-11-19 OssDsign OssDsign AB (publ) publicerar delårsrapport för tredje kvartalet 2019 Rapporter Ladda ner | Visa Stäng
2019-11-14 OssDsign OssDsign AB: OssDsign deltar i investerarpresentationer Pressreleaser Ladda ner | Visa Stäng
2019-11-07 OssDsign OssDsign AB: Nya data visar positiva resultat vid användning av OSSDSIGN Cranial PSI för kraniell rekonstruktion Pressreleaser Ladda ner | Visa Stäng
2019-11-07 OssDsign OssDsign AB: New data show positive outcome when using OSSDSIGN Cranial PSI for cranial reconstruction Pressreleaser Ladda ner | Visa Stäng
2019-10-23 OssDsign OssDsign AB: OssDsign is granted a new European patent related to the company's ceramic material technology Pressreleaser Ladda ner | Visa Stäng
2019-10-23 OssDsign OssDsign AB: OssDsign beviljas nytt europeiskt patent avseende bolagets keramiska materialteknologi Pressreleaser Ladda ner | Visa Stäng
2019-10-14 OssDsign OssDsign AB erhåller FDA-godkännande för Cranial PSI Accessories och stärker därmed bolagets kommersiella position i USA Pressreleaser Ladda ner | Visa Stäng
2019-10-14 OssDsign OssDsign AB: OssDsign receives US FDA clearance for Cranial PSI Accessories - strengthening business position in the US Pressreleaser Ladda ner | Visa Stäng
2019-08-21 OssDsign OssDsign AB (publ) publishes Q2 2019 interim report Rapporter Ladda ner | Visa Stäng
2019-08-21 OssDsign OssDsign AB (publ) publicerar delårsrapport för andra kvartalet 2019 Rapporter Ladda ner | Visa Stäng
2019-08-21 OssDsign OssDsign AB (publ) publicerar delårsrapport för andra kvartalet 2019 Rapporter Ladda ner | Visa Stäng
2019-08-21 OssDsign OssDsign AB (publ) publishes Q2 2019 interim report Rapporter Ladda ner | Visa Stäng
2019-08-09 OssDsign OssDsign AB (publ) har ansökt om regulatoriskt godkännande i Japan och inleder förberedelser för lansering av OssDsign Cranial Pressreleaser Ladda ner | Visa Stäng
2019-08-09 OssDsign OssDsign AB (publ) initiates commercial preparations for launch in Japan following regulatory filing for OssDsign Cranial Pressreleaser Ladda ner | Visa Stäng
2019-06-20 OssDsign Announcement on stabilization measures in OssDsign AB (publ) during the period from June 17 to June 20, 2019 and termination of the stabilization period Pressreleaser Ladda ner | Visa Stäng
2019-06-20 OssDsign Meddelande om stabiliseringsåtgärder i OssDsign AB (publ) under perioden 17 - 20 juni 2019 och avslutande av stabiliseringsperioden Pressreleaser Ladda ner | Visa Stäng
2019-06-18 OssDsign Correction of announcement on stabilization measures in OssDsign AB (publ) during the period from June 10 to June 14, 2019 Pressreleaser Ladda ner | Visa Stäng
2019-06-18 OssDsign Korrigering av meddelande om stabiliseringsåtgärder i OssDsign AB (publ) under perioden 10 - 14 juni 2019 Pressreleaser Ladda ner | Visa Stäng
2019-06-14 OssDsign Meddelande om stabiliseringsåtgärder i OssDsign AB (publ) under perioden 10 - 14 juni 2019 Pressreleaser Ladda ner | Visa Stäng
2019-06-14 OssDsign Announcement on stabilization measures in OssDsign AB (publ) during the period from June 10 to June 14, 2019 Pressreleaser Ladda ner | Visa Stäng
2019-06-07 OssDsign Announcement on stabilization measures in OssDsign AB (publ) during the period from May 31 to June 7, 2019 Pressreleaser Ladda ner | Visa Stäng
2019-06-07 OssDsign Meddelande om stabiliseringsåtgärder i OssDsign AB (publ) under perioden 31 maj - 7 juni 2019 Pressreleaser Ladda ner | Visa Stäng
2019-05-29 OssDsign Announcement on stabilization measures in OssDsign AB (publ) during the period from May 24 to May 29, 2019 Pressreleaser Ladda ner | Visa Stäng
2019-05-29 OssDsign Meddelande om stabiliseringsåtgärder i OssDsign AB (publ) under perioden 24 - 29 maj 2019 Pressreleaser Ladda ner | Visa Stäng
2019-05-28 OssDsign OssDsign AB (publ) further strengthens its patent portfolio Pressreleaser Ladda ner | Visa Stäng
2019-05-28 OssDsign OssDsign AB (publ) förstärker patentportföljen ytterligare Pressreleaser Ladda ner | Visa Stäng
2019-05-23 OssDsign OssDsign AB (publ) receives initial positive notice regarding reimbursement for OSSDSIGN Cranial PSI in France Pressreleaser Ladda ner | Visa Stäng
2019-05-23 OssDsign OssDsign AB (publ) erhåller initialt positivt besked angående ersättning för OSSDSIGN Cranial PSI i Frankrike Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

19 Nov 2019 | Kvartalsrapport 2019-Q3
13 Feb 2020 | Bokslutskommuniké 2019
16 Apr 2020 | Årsstämma 2019
17 Apr 2020 | Årligutdelning
13 May 2020 | Kvartalsrapport 2020-Q1
20 May 2020 | Årsstämma 2019
22 May 2020 | Årligutdelning
19 Aug 2020 | Kvartalsrapport 2020-Q2
11 Nov 2020 | Kvartalsrapport 2020-Q3
11 Feb 2021 | Bokslutskommuniké 2020
17 Feb 2021 | Bokslutskommuniké 2020
9 Apr 2021 | Extrastämma 2021
12 May 2021 | Kvartalsrapport 2021-Q1
19 May 2021 | Årsstämma 2020
20 May 2021 | Årligutdelning
18 Aug 2021 | Kvartalsrapport 2021-Q2
17 Nov 2021 | Kvartalsrapport 2021-Q3

epaccess.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?

Jag godkänner